Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
Chugai Pharmaceutical has inked a global licensing pact with Swiss-based Galderma Pharma S.A. for its hope-to-be blockbuster nemolizumab, an antibody being developed for the treatment of atopic dermatitis and pruritus in hemodialysis patients, the two companies said on July 21.…
To read the full story
Related Article
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
BUSINESS
- Parexel Revs Up AI Drive, Targets 6-Month Trial Time Cut
October 8, 2026
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…